Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

Robert I. Haddad, Kevin J. Harrington, Makoto Tahara, +22

Journal of Clinical Oncology

Kaempferol induces apoptosis in human HCT116 colon cancer cells via the Ataxia-Telangiectasia Mutated-p53 pathway with the involvement of p53 Upregulated Modulator of Apoptosis

Wei Li, Bingna Du, Tianyi Wang, +2

Chemico-Biological Interactions

Ataxia-telangiectasia Mutated-p53 PathwayOncologyOncogenic AgentMedicineApoptosis +7

Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141

Maura L. Gillison, George R. Blumenschein, Jérôme Fayette, +17

The Oncologist

Neck CancerNivolumab Versus IcCancer ManagementOncologyCheckmate 141 +14

MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma

Zhuochao Liu, Junxiang Wen, Chuanlong Wu, +9

Aging

<p>Potential Diagnostic Value Of Combining Inflammatory Cell Ratios With Carcinoembryonic Antigen For Colorectal Cancer</p>

Xinxin Li, Dongming Guo, Ling‐Yu Chu, +4

Cancer Management and Research

A PD1 targeted nano-delivery system based on epigenetic alterations of T cell responses in the treatment of gastric cancer

Nan Hu, Wei Li, Yidong Hong, +5

Molecular Therapy — Oncolytics

Peripheral CD4+ naïve/memory ratio is an independent predictor of survival in non-small cell lung cancer

Peng Yang, Junhong Ma, Xin Yang, +1

Oncotarget

The associations of two novel inflammation indexes, systemic immune-inflammation index (SII) and system inflammation response index (SIRI), with periodontitis: evidence from NHANES 2009–2014

Shiyi Luo, Zefei Liu, Ruofeng Jiao, +5

Clinical Oral Investigations

InflammationNovel Inflammation IndexesNhanes 2009–2014ImmunologyInflammation Biology +7

Association between red blood cell distribution width and Henoch–Schonlein purpura nephritis

Wei Li, Jianhua Mao, Yan‐Xiang Pan

Medicine

Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial

Jifang Gong, Junning Cao, Qingyuan Zhang, +18

Cancer Immunology Immunotherapy